Related Experiment Video
Updated: Jan 31, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Apatinib inhibits tumor growth and angiogenesis in PNET models
Shan Wu1,2, Jianjun Zhou2, Jing Guo3
1College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, People's Republic of China.
Abstract:
Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear. The aim of this study was to compare the antitumor efficacy of apatinib with that of the standard PNET drug sunitinib in our subcutaneous and liver metastasis models of insulinoma and non-functional PNET. Our results revealed that apatinib had a generally comparable or even superior antitumor effect to that of sunitinib on primary PNET, and it inhibited angiogenesis without directly causing tumor cell cytotoxicity. Apatinib inhibited the tumor in a dose-dependent manner, and the high dose was well tolerated in mice. We also found that the apatinib efficacy in liver metastasis models was cell-type (disease) selective. Although apatinib efficiently inhibited INR1G9-represented non-functional PNET liver metastasis, it led to the emergence of a hypoxic area in the INS-1-represented insulinoma and promoted liver metastasis. Our study demonstrated that apatinib has promise for clinical applications in certain malignant PNETs, and the application of anti-angiogenesis drugs to benign insulinomas may require careful consideration.
Insights
Apatinib shows promise for treating pancreatic neuroendocrine tumors (PNETs), comparable or superior to sunitinib. However, its efficacy is cell-type selective, potentially promoting metastasis in insulinomas.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Angiogenesis is crucial for pancreatic neuroendocrine tumor (PNET) growth and metastasis.
- Apatinib, a KDR inhibitor, targets angiogenesis and is used for other cancers.
- The efficacy of apatinib in PNETs requires investigation.
Purpose of the Study:
- To compare the antitumor efficacy of apatinib with sunitinib in PNET models.
- To evaluate apatinib's effects on angiogenesis and tumor cell cytotoxicity.
- To assess apatinib's efficacy in subcutaneous and liver metastasis models of insulinoma and non-functional PNET.
Main Methods:
- Utilized subcutaneous and liver metastasis models of insulinoma and non-functional PNET.
- Administered apatinib and sunitinib to evaluate antitumor effects.
- Assessed dose-dependency and tolerability of apatinib in mice.
- Analyzed cell-type selectivity of apatinib in liver metastasis models.
Main Results:
- Apatinib demonstrated comparable or superior antitumor effects to sunitinib in primary PNET.
- Apatinib inhibited angiogenesis without direct tumor cell cytotoxicity.
- Efficacy of apatinib in liver metastasis was cell-type selective.
- Apatinib inhibited non-functional PNET metastasis but promoted insulinoma liver metastasis by inducing hypoxia.
Conclusions:
- Apatinib shows potential for treating certain malignant PNETs.
- Anti-angiogenesis therapy with apatinib may require careful consideration for benign insulinomas.
- Further research is needed to understand apatinib's selective efficacy in PNETs.
Related Concept Videos
Feedback Inhibition
Mechanism of Angiogenesis
Growth Models with Integration: Problem Solving
Exponential Equations for Modeling Growth
Enzyme Inhibition
Population Growth

